vs
AIR LEASE CORP（AL）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是AIR LEASE CORP的1.6倍（$219.9M vs $140.8M），AIR LEASE CORP净利率更高（128.5% vs -1.0%，领先129.5%），AIR LEASE CORP同比增速更快（90.4% vs 2.0%），AIR LEASE CORP自由现金流更多（$342.1M vs $16.8M），过去两年AIR LEASE CORP的营收复合增速更高（69.6% vs 8.0%）
航空租赁公司（ALC）是2010年成立的美国飞机租赁企业，由史蒂文·F·乌德瓦-哈齐执掌运营。公司直接向波音、空客、巴航工业、ATR采购全新商用飞机，为全球各地航空公司客户提供专业的飞机租赁及融资服务。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
AL vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.6倍
$140.8M
营收增速更快
AL
高出88.5%
2.0%
净利率更高
AL
高出129.5%
-1.0%
自由现金流更多
AL
多$325.3M
$16.8M
两年增速更快
AL
近两年复合增速
8.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $140.8M | $219.9M |
| 净利润 | $180.9M | $-2.2M |
| 毛利率 | — | 71.1% |
| 营业利润率 | — | 0.2% |
| 净利率 | 128.5% | -1.0% |
| 营收同比 | 90.4% | 2.0% |
| 净利润同比 | 60.2% | 92.4% |
| 每股收益（稀释后） | $1.49 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ALOFIX
| Q4 25 | $140.8M | $219.9M | ||
| Q3 25 | $44.5M | $205.6M | ||
| Q2 25 | $53.0M | $203.1M | ||
| Q1 25 | $92.9M | $193.6M | ||
| Q4 24 | $74.0M | $215.7M | ||
| Q3 24 | $65.0M | $196.6M | ||
| Q2 24 | $57.8M | $198.6M | ||
| Q1 24 | $49.0M | $188.6M |
净利润ALOFIX
| Q4 25 | $180.9M | $-2.2M | ||
| Q3 25 | $146.5M | $-22.8M | ||
| Q2 25 | $385.2M | $-14.1M | ||
| Q1 25 | $375.8M | $-53.1M | ||
| Q4 24 | $112.9M | $-29.1M | ||
| Q3 24 | $104.0M | $-27.4M | ||
| Q2 24 | $102.9M | $-33.4M | ||
| Q1 24 | $107.9M | $-36.0M |
毛利率ALOFIX
| Q4 25 | — | 71.1% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 68.7% | ||
| Q1 25 | — | 62.8% | ||
| Q4 24 | — | 69.0% | ||
| Q3 24 | — | 68.7% | ||
| Q2 24 | — | 67.8% | ||
| Q1 24 | — | 67.5% |
营业利润率ALOFIX
| Q4 25 | — | 0.2% | ||
| Q3 25 | — | -8.3% | ||
| Q2 25 | — | -7.9% | ||
| Q1 25 | — | -25.2% | ||
| Q4 24 | — | -5.3% | ||
| Q3 24 | — | -9.6% | ||
| Q2 24 | — | -12.5% | ||
| Q1 24 | — | -15.6% |
净利率ALOFIX
| Q4 25 | 128.5% | -1.0% | ||
| Q3 25 | 329.2% | -11.1% | ||
| Q2 25 | 726.9% | -6.9% | ||
| Q1 25 | 404.5% | -27.4% | ||
| Q4 24 | 152.7% | -13.5% | ||
| Q3 24 | 160.0% | -13.9% | ||
| Q2 24 | 178.2% | -16.8% | ||
| Q1 24 | 220.2% | -19.1% |
每股收益（稀释后）ALOFIX
| Q4 25 | $1.49 | $-0.05 | ||
| Q3 25 | $1.21 | $-0.57 | ||
| Q2 25 | $3.33 | $-0.36 | ||
| Q1 25 | $3.26 | $-1.35 | ||
| Q4 24 | $0.83 | $-0.76 | ||
| Q3 24 | $0.82 | $-0.71 | ||
| Q2 24 | $0.81 | $-0.88 | ||
| Q1 24 | $0.87 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.4M | $82.0M |
| 总债务越低越好 | $19.7B | — |
| 股东权益账面价值 | $8.5B | $450.0M |
| 总资产 | $32.9B | $850.6M |
| 负债/权益比越低杠杆越低 | 2.33× | — |
8季度趋势，按日历期对齐
现金及短期投资ALOFIX
| Q4 25 | $466.4M | $82.0M | ||
| Q3 25 | $452.2M | $62.9M | ||
| Q2 25 | $454.8M | $65.6M | ||
| Q1 25 | $456.6M | $58.0M | ||
| Q4 24 | $472.6M | $83.2M | ||
| Q3 24 | $460.8M | $30.1M | ||
| Q2 24 | $454.1M | $26.4M | ||
| Q1 24 | $554.4M | $27.0M |
总债务ALOFIX
| Q4 25 | $19.7B | — | ||
| Q3 25 | $20.2B | $157.2M | ||
| Q2 25 | $20.3B | $157.0M | ||
| Q1 25 | $19.9B | $156.9M | ||
| Q4 24 | $20.2B | $157.0M | ||
| Q3 24 | $20.2B | $118.5M | ||
| Q2 24 | $19.7B | $118.0M | ||
| Q1 24 | $19.5B | $118.2M |
股东权益ALOFIX
| Q4 25 | $8.5B | $450.0M | ||
| Q3 25 | $8.3B | $442.5M | ||
| Q2 25 | $8.2B | $458.3M | ||
| Q1 25 | $7.9B | $458.3M | ||
| Q4 24 | $7.5B | $503.1M | ||
| Q3 24 | $7.7B | $525.9M | ||
| Q2 24 | $7.3B | $546.0M | ||
| Q1 24 | $7.2B | $570.3M |
总资产ALOFIX
| Q4 25 | $32.9B | $850.6M | ||
| Q3 25 | $33.4B | $832.6M | ||
| Q2 25 | $33.3B | $837.2M | ||
| Q1 25 | $32.4B | $823.1M | ||
| Q4 24 | $32.3B | $893.3M | ||
| Q3 24 | $32.2B | $867.9M | ||
| Q2 24 | $31.0B | $882.0M | ||
| Q1 24 | $30.9B | $906.0M |
负债/权益比ALOFIX
| Q4 25 | 2.33× | — | ||
| Q3 25 | 2.42× | 0.36× | ||
| Q2 25 | 2.47× | 0.34× | ||
| Q1 25 | 2.53× | 0.34× | ||
| Q4 24 | 2.68× | 0.31× | ||
| Q3 24 | 2.63× | 0.23× | ||
| Q2 24 | 2.69× | 0.22× | ||
| Q1 24 | 2.69× | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $414.1M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $342.1M | $16.8M |
| 自由现金流率自由现金流/营收 | 242.9% | 7.6% |
| 资本支出强度资本支出/营收 | 51.1% | 4.9% |
| 现金转化率经营现金流/净利润 | 2.29× | — |
| 过去12个月自由现金流最近4个季度 | $1.5B | $-1.3M |
8季度趋势，按日历期对齐
经营现金流ALOFIX
| Q4 25 | $414.1M | $27.7M | ||
| Q3 25 | $458.6M | $12.4M | ||
| Q2 25 | $473.6M | $11.6M | ||
| Q1 25 | $388.3M | $-18.4M | ||
| Q4 24 | $430.0M | $23.7M | ||
| Q3 24 | $461.9M | $11.7M | ||
| Q2 24 | $413.8M | $9.0M | ||
| Q1 24 | $371.3M | $-18.6M |
自由现金流ALOFIX
| Q4 25 | $342.1M | $16.8M | ||
| Q3 25 | $412.3M | $2.5M | ||
| Q2 25 | $427.1M | $4.5M | ||
| Q1 25 | $315.5M | $-25.1M | ||
| Q4 24 | $326.8M | $15.2M | ||
| Q3 24 | $369.8M | $6.3M | ||
| Q2 24 | $346.4M | $-360.0K | ||
| Q1 24 | $246.8M | $-29.1M |
自由现金流率ALOFIX
| Q4 25 | 242.9% | 7.6% | ||
| Q3 25 | 926.6% | 1.2% | ||
| Q2 25 | 806.0% | 2.2% | ||
| Q1 25 | 339.5% | -13.0% | ||
| Q4 24 | 441.8% | 7.0% | ||
| Q3 24 | 569.1% | 3.2% | ||
| Q2 24 | 599.5% | -0.2% | ||
| Q1 24 | 503.8% | -15.4% |
资本支出强度ALOFIX
| Q4 25 | 51.1% | 4.9% | ||
| Q3 25 | 104.1% | 4.8% | ||
| Q2 25 | 87.8% | 3.5% | ||
| Q1 25 | 78.4% | 3.5% | ||
| Q4 24 | 139.6% | 4.0% | ||
| Q3 24 | 141.7% | 2.7% | ||
| Q2 24 | 116.7% | 4.7% | ||
| Q1 24 | 254.3% | 5.6% |
现金转化率ALOFIX
| Q4 25 | 2.29× | — | ||
| Q3 25 | 3.13× | — | ||
| Q2 25 | 1.23× | — | ||
| Q1 25 | 1.03× | — | ||
| Q4 24 | 3.81× | — | ||
| Q3 24 | 4.44× | — | ||
| Q2 24 | 4.02× | — | ||
| Q1 24 | 3.44× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AL
暂无分部数据
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
